Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 20, 2004

Primary Completion Date

October 25, 2006

Study Completion Date

October 25, 2006

Conditions
Solid Tumours
Interventions
DRUG

SB-715992

SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.

DRUG

carboplatin

Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.

Trial Locations (2)

37203

GSK Investigational Site, Nashville

NE4 6BE

GSK Investigational Site, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY